Test Price
2,800 AEDโ Home Collection Available
CACNA1A Gene Analysis for Familial Hemiplegic Migraine Type 1 โ Comprehensive Genetic Test in UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity โ ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance โ Complimentary telephonic post-test result interpretation with a DHA-licensed Consultant Medical Genetics specialist.
- Insurance โ Direct Billing Verification available via WhatsApp at +971 54 548 8731.
This comprehensive NGS-based genetic test delivers definitive molecular confirmation of Familial Hemiplegic Migraine Type 1 through full-gene sequencing of CACNA1A, enabling precise diagnosis, familial risk stratification, and informed clinical management under DHA regulatory oversight.
Test Overview & Methodology
This Genetic Test comprehensively analyses the CACNA1A gene to identify pathogenic variants responsible for Familial Hemiplegic Migraine Type 1 (FHM1), an autosomal dominant neurological disorder. The result empowers precise diagnosis, risk assessment for family members, and informed treatment strategies using next-generation sequencing technology.
| Feature | Our Test (NGS โ CACNA1A Comprehensive) | Closest Alternative (SingleโExon Sequencing) |
|---|---|---|
| Precision | Full gene coverage, detects point mutations, indels, copy number variants | Limited to a single exon; misses deep intronic or large rearrangements |
| Methodology | Next Generation Sequencing (Illumina platform), read depth >100ร, 99.9% sensitivity | Sanger sequencing โ lower resolution, manual interpretation |
| Turnaround | 3โ4 Weeks | 6โ8 Weeks typical |
Physician Insight & Safety Protocols
โAs a Consultant Medical Genetics specialist, I emphasize that comprehensive CACNA1A gene sequencing via NGS technology provides definitive molecular confirmation for Familial Hemiplegic Migraine Type 1. This analysis enables precise risk stratification for at-risk family members and guides targeted therapeutic interventions. A negative result does not completely exclude the diagnosis, and results must always be interpreted within the full clinical context, including aura characteristics and family pedigree analysis.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Precautions for Patients and Referring Clinicians
Clinical Advisory
This genetic test is intended solely for molecular confirmation of suspected Familial Hemiplegic Migraine Type 1 in individuals with a documented clinical history and family pedigree consistent with autosomal dominant inheritance. It is not indicated for acute migraine diagnosis, routine headache screening, or asymptomatic individuals without a clear family history. All results must be correlated with a neurological examination and interpreted by a qualified genetics specialist before any therapeutic decisions are made.
Exclusion Criteria and Emergency Red Flags
Contraindications and Urgent Warning Signs
Do not discontinue prescribed medication without consulting your doctor.
- Exclusion Criteria: This test is not indicated for individuals without a confirmed or strongly suspected family history of hemiplegic migraine. Minors under 18 years require legal guardian consent in accordance with UAE Federal Law and DHA regulatory guidelines for genetic testing in pediatric populations.
- Emergency Red Flags: If you experience sudden thunderclap headache, one-sided paralysis accompanied by confusion, vision loss, or seizure, seek immediate emergency medical attention. These symptoms may indicate acute cerebrovascular pathology requiring urgent neurological evaluation.
Patient FAQ & Clinical Guidance
1. What is the CACNA1A genetic test and what does it detect?
This next-generation sequencing test identifies pathogenic mutations in the CACNA1A gene with 99.9% diagnostic sensitivity, confirming familial hemiplegic migraine type 1. Full-gene coverage ensures detection of point mutations, small insertions and deletions, and copy number variants that alternative methods may miss.
2. Who should consider undergoing this test in the UAE?
Individuals with recurrent attacks of hemiplegic migraine and a documented family history of similar episodes should undergo CACNA1A analysis after evaluation by a neurologist or medical genetics specialist. First-degree relatives of a confirmed FHM1 proband may also benefit from predictive testing following appropriate genetic counselling.
3. How is the sample collected, and is home collection available?
A standard peripheral whole blood sample or dried blood spot is collected by a DHA-licensed phlebotomist at your residence through our VIP Mobile Phlebotomy service. Temperature-controlled cold-chain logistics ensure sample integrity during transport to our ISO 9001:2015 accredited laboratory. Home collection is available daily from 8 AM to 11 PM across all emirates.
4. How long does it take to receive results, and how are they delivered?
The standard turnaround time is 3 to 4 weeks from sample receipt at the laboratory. Results are delivered via secure digital report, and a complimentary telephonic post-test consultation with a Consultant Medical Genetics specialist is provided to interpret findings and discuss clinical implications.
5. Does insurance cover this test, and how can I verify my coverage?
Direct billing verification is available through our insurance team. Please contact us via WhatsApp at +971 54 548 8731 to confirm your coverage and eligibility before scheduling sample collection.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
Data Privacy: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data minimization, and purpose limitation principles are strictly enforced throughout the testing lifecycle.
Clinical Safety & Liability: All clinical testing procedures, patient safety protocols, and informed consent processes adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Accreditation: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139). All genetic testing is performed under the direct supervision of DHA-licensed medical professionals within a licensed diagnostic facility.
Clinical & Logistical Metadata
| Test Name | CACNA1A Gene Analysis (Familial Hemiplegic Migraine Type 1) โ Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Dried Blood Spot |
| Methodology Used | Next Generation Sequencing (NGS) โ Illumina Platform, >100ร read depth |
| ICD-10-CM Code | G43.10 |
| LOINC Code | 94244-1 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians